CLINICAL IMMUNOLOGY
Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients – preliminary study
Submission date: 2015-08-17
Acceptance date: 2015-08-19
Publication date: 2015-10-15
Cent Eur J Immunol 2015;40(3):354-359
KEYWORDS
ABSTRACT
Background: Fingolimod is a drug administered orally to adult patients treated for relapsing remitting course of multiple sclerosis (MS). Mode of action of fingolimod is based on intense S1P1 receptor stimulation and “arresting” lymphocytes in lymphatic organs. Objective of the research was to assess changes in the frequencies of basic lymphocyte subsets in patients treated for multiple sclerosis with the use of fingolimod.
Material and methods: Study group comprised of 25 previously untreated adult patients with MS. Venous blood samples were collected from each patient before and one month, three months and six months after treatment initiation. Peripheral blood lymphocyte immunophenotype was assessed with a set of monoclonal antibodies bounded to appropriate fluorochromes and flow cytometer FACSCalibur. Statistical analysis of the results was conducted using Statistica 9.0 software.
Results: Before fingolimod administration median of lymphocyte subsets percentage in each patient was in reference range. After 1 month of treatment we noticed significant changes in frequencies of following lymphocyte subsets: NK cells – 51.22% (p = 0.016), T CD4+ cells – 11.58% (p = 0.01), T CD4+:T CD8+ cells ratio – 0.61 (p = 0.005). After 3 and 6 months of treatment there was further increase of deviation from normal state.
Conclusions: The use of fingolimod is associated with profound changes in lymphocyte subsets distribution, which might bear a risk of the development of cellular immune deficiency symptoms.
Material and methods: Study group comprised of 25 previously untreated adult patients with MS. Venous blood samples were collected from each patient before and one month, three months and six months after treatment initiation. Peripheral blood lymphocyte immunophenotype was assessed with a set of monoclonal antibodies bounded to appropriate fluorochromes and flow cytometer FACSCalibur. Statistical analysis of the results was conducted using Statistica 9.0 software.
Results: Before fingolimod administration median of lymphocyte subsets percentage in each patient was in reference range. After 1 month of treatment we noticed significant changes in frequencies of following lymphocyte subsets: NK cells – 51.22% (p = 0.016), T CD4+ cells – 11.58% (p = 0.01), T CD4+:T CD8+ cells ratio – 0.61 (p = 0.005). After 3 and 6 months of treatment there was further increase of deviation from normal state.
Conclusions: The use of fingolimod is associated with profound changes in lymphocyte subsets distribution, which might bear a risk of the development of cellular immune deficiency symptoms.
REFERENCES (36)
1.
Jaśkiewicz E (2004): Epitopes on myelin proteins recognized by autoantibodies present in multiple sclerosis patients. Postepy Hig Med Dosw 58: 472-482.
2.
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000): Multiple sclerosis. N Engl J Med 343: 938-952.
3.
O’Connor KC, Bar-Or A, Hafler DA (2001): The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol 21: 81-92.
4.
Zawada M (2012): Potential pathogens in multiple sclerosis (MS). Postepy Hig Med Dosw 66: 758-770.
5.
Dalakas MC (2006): B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther 112: 57-70.
6.
Goverman J (2009): Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 9: 393-407.
7.
Lalive PH (2008): Autoantibodies in inflammatory demyelinating diseases of the central nervous system. Swiss Med Wkly 138: 692-707.
8.
Lis J, Jarząb A, Witkowska D (2012): Rola mimikry molekularnej w etiologii schorzeń o charakterze autoimmunizacyjnym. Postępy Hig Med Dośw 66: 475-491.
9.
Gbadamosi J, Buhmann C, Tessmer W, et al. (2003): Effects of mitoxantrone on multiple sclerosis patients lymphocyte subpopulations and production of immunoglobulin, TNF-αlpha and IL-10. Eur Neurol 49: 137-141.
10.
Goffette S, van Pesch V, Vanoverschelde JL, et al. (2005): Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. J Neurol 252: 1217-1222.
12.
Szwed M (2014): Mitoxantrone – an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis. Postepy Hig Med Dosw 68: 198-208.
13.
Bayas A (2013): Improving adherence to injectable disease-modifying drugs in multiple sclerosis. Expert Opin Drug Deliv 10: 285-287.
14.
Nogales-Gaete J, Aracena R, Díaz V (2012): Neuropsychological assessment of patients with relapsing remitting multiple sclerosis prior to the use of immunomodulatory drugs. Rev Med Chil 140: 1437-1444.
15.
Cruz VT, Fonseca J (2014): Central effects of fingolimod. Rev Neurol 59: 121-128.
16.
Groves A, Kihara Y, Chun J (2013): Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 328: 9-18.
17.
Chun J, Hartung HP (2010): Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33: 91-101.
18.
Waters L, Mandalia S, Randell P, et al. (2008): The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 46: 1617-1623.
19.
Piwowar A (2014): The advanced oxidation protein products as potential diagnostic and prognostic factor in diseases of the indicated participation of oxidative stress. Postepy Hig Med Dosw (Online) 68: 446-458.
20.
Hotchkiss RS, Tinsley KW, Swanson PE, et al. (2001): Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 166: 6952-6963.
21.
Pelekanou A, Tsangaris I, Kotsaki A, et al. (2009): Decrease of CD4-lymphocytes and apoptosis of CD14-monocytes are characteristic alterations in sepsis caused by ventilator-associated pneumonia: results from an observational study. Crit Care 13: R172.
22.
Gupta M, Spiropoulou C, Rollin PE (2007): Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro. Virology 364: 45-54.
23.
Konikowska K, Regulska-Ilow B (2014): The role of diet in multiple sclerosis. Postepy Hig Med Dosw (Online) 68: 325-333.
24.
Wikby A, Maxson P, Olsson J, et al. (1998): Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation responses and non-survival in the very old: the Swedish longitudinal OCTO-immune study. Mech Ageing Dev 102: 187-198.
25.
De Paoli P, Battistin S, Santini GF (1988): Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population. Clin Immunol Immunopathol 4: 290-296.
26.
Walker UA, Warnatz K (2006): Idiopathic CD4 lymphocytopenia. Curr Opin Rheumatol 18: 389-395.
27.
Cohen JA, Barkhof F, Comi G, et al. (2010): Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402-415.
28.
Uccelli A, Ginocchio F, Mancardi GL, Bassetti M (2011): Primary varicella zoster infection associated with fingolimod treatment. Neurology 76: 1023-1024.
29.
Gross CM, Baumgartner A, Rauer S, Stich O (2012): Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Neurology 79: 2006-2007.
30.
Ratchford JN, Costello K, Reich DS, Calabresi PA (2012): Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology 79: 2002-2004.
31.
Ricklin ME, Lorscheider J, Waschbisch A, et al. (2013): T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Neurology 81: 174-181.
33.
Soliman DS, Sabbagh AA, Omri HE (2014): Rare aggressive natural killer cell leukemia presented with bone marrow fibrosis – a diagnostic challenge. Springerplus 3: 390.
34.
Ligthart GJ, van Vlokhoven PC, Schuit HR, Hijmans W (1986): The expanded null cell compartment in ageing: increase in the number of natural killer cells and changes in T-cell and NK-cell subsets in human blood. Immunology 59: 353-357.
35.
Krishnaraj R, Blandford G (1988): Age-associated alterations in human natural killer cells. 2. Increased frequency of selective NK subsets. Cell Immunol 114: 137-148.
36.
Adamiak M, Tokarz-Deptuła B, Deptuła W (2014): Characteristic of innate lymphoid cells (ILC). Postepy Hig Med Dosw (Online) 68: 1464-1471.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
